126 related articles for article (PubMed ID: 38388076)
1. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
Sicilia Pozo MLN; Pena Pardo FJ; Amo Salas M; Cruz Montijano M; Torres Hernández J; Padilla Bermejo A; Montalbán Méndez C; Zhao Montero M; Soriano Castrejón Á; García Vicente AM
Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy.
Bojarsky M; Baran JA; Halada S; Isaza A; Zhuang H; States L; Grant FD; Robbins S; Sisko L; Ricarte-Filho JC; Kazahaya K; Adzick NS; Mostoufi-Moab S; Bauer AJ
J Clin Endocrinol Metab; 2023 Nov; 108(12):3338-3344. PubMed ID: 37265226
[TBL] [Abstract][Full Text] [Related]
3. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
Pan M; Li Z; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
[TBL] [Abstract][Full Text] [Related]
4. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract][Full Text] [Related]
5. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study.
Cistaro A; Quartuccio N; Garganese MC; Villani MF; Altini C; Pizzoferro M; Piccardo A; Cabria M; Massollo M; Maghnie M; Campennì A; Siracusa M; Baldari S; Panareo S; Urso L; Bartolomei M; De Palma D; Grossi A; Mazzoletti A; Dondi F; Bertagna F; Giubbini R; Albano D
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1374-1385. PubMed ID: 34664092
[TBL] [Abstract][Full Text] [Related]
7. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.
Nóbrega G; Cavalcanti M; Leite V; Vilar L; Brandão SCS
Endocrine; 2022 Jun; 76(3):642-647. PubMed ID: 35237910
[TBL] [Abstract][Full Text] [Related]
8. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
9. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation.
Hong CM; Lee WK; Jeong SY; Lee SW; Ahn BC; Lee J
Nucl Med Commun; 2014 Nov; 35(11):1119-26. PubMed ID: 25144561
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma.
Shi ZY; Zhang SX; Fan D; Li CH; Cheng ZH; Xue Y; Wu LX; Lu KY; Yang SY; Cheng Y; Wu ZF; Gao C; Li XF; Liu HY; Li SJ
Front Immunol; 2022; 13():901263. PubMed ID: 35844520
[TBL] [Abstract][Full Text] [Related]
11. Avidity and Outcomes of Radioiodine Therapy for Distant Metastasis of Distinct Types of Differentiated Thyroid Cancer.
Simões-Pereira J; Mourinho N; Ferreira TC; Limbert E; Cavaco BM; Leite V
J Clin Endocrinol Metab; 2021 Sep; 106(10):e3911-e3922. PubMed ID: 34134139
[TBL] [Abstract][Full Text] [Related]
12. Factors Influencing the Success of the First Radioiodine Therapy for Differentiated Thyroid Carcinoma.
Claimon A; Pusuwan P; Khiewvan B
J Med Assoc Thai; 2017 Feb; 100(2):207-18. PubMed ID: 29916638
[TBL] [Abstract][Full Text] [Related]
13. Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China.
Liu Q; Yin M; Li G
Front Endocrinol (Lausanne); 2021; 12():774275. PubMed ID: 34975751
[TBL] [Abstract][Full Text] [Related]
14. The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer.
Albano D; Dondi F; Zilioli V; Panarotto MB; Galani A; Cappelli C; Bertagna F; Giubbini R; Casella C
Ann Nucl Med; 2021 Oct; 35(10):1089-1099. PubMed ID: 34152569
[TBL] [Abstract][Full Text] [Related]
15. Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.
Tian T; Qi Z; Huang S; Wang H; Huang R
J Clin Endocrinol Metab; 2023 Jul; 108(8):2033-2041. PubMed ID: 36715264
[TBL] [Abstract][Full Text] [Related]
16. Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer.
Sun Y; Sun Q; Tian J; He X
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1413-e1423. PubMed ID: 37167097
[TBL] [Abstract][Full Text] [Related]
17. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.
Luster M; Aktolun C; Amendoeira I; Barczyński M; Bible KC; Duntas LH; Elisei R; Handkiewicz-Junak D; Hoffmann M; Jarząb B; Leenhardt L; Musholt TJ; Newbold K; Nixon IJ; Smit J; Sobrinho-Simões M; Sosa JA; Tuttle RM; Verburg FA; Wartofsky L; Führer D
Thyroid; 2019 Jan; 29(1):7-26. PubMed ID: 30484394
[TBL] [Abstract][Full Text] [Related]
18. Comparison of body iodine pool assessment methods before radioiodine therapy.
Genc M; Yildirim A; Yildirim N
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(2):107-112. PubMed ID: 38331249
[TBL] [Abstract][Full Text] [Related]
19. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
[TBL] [Abstract][Full Text] [Related]
20. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response.
Vaisman F; Tala H; Grewal R; Tuttle RM
Thyroid; 2011 Dec; 21(12):1317-22. PubMed ID: 22136267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
